menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    CSL`s Andembry S.C. Injection Approved In Japan For HAE

    PR NEWSWIRE

    EMA Approves CSL`s Andembry® for Hereditary Angioedema

    PR NEWSWIRE

    CSL Behring’s Hemgenix® Shows Sustained Efficacy in Hemophilia B

    PR NEWSWIRE

    First Patients Treated With Hemgenix Therapy For Haemophilia B

    PHARMAWEB

    CSL`s Garadacimab Approved By CHMP For Hereditary Angioedema

    PR NEWSWIRE

    CSL Behring shuts down California cell and gene therapy R&D site

    FIERCE BIOTECH

    CSL Behring Treats First European Patients With HEMGENIX Gene Therapy

    GLOBENEWSWIRE

    UniQure, with sale of plant, outsources Hemgenix manufacturing

    BIOPHARMADIVE

    CSL Behring cuts headcount by 65 at Illinois plant

    FIERCE PHARMA

    Midas Team Readies For Pharma-Cup 2024 Soccer Challenge

    PRESS RELEASE

    Kyowa`s Orchard hopes $4.25M gene therapy price tag bears fruit

    FIERCE PHARMA

    CSL and uniQure unveil three-year data for one-time hemophilia B gene therapy

    ENDPTS

    CSL Behring Announces Availability of Hizentra 10g Prefilled Syringe

    PR NEWSWIRE

    CSL Behring Demonstrates Continued Commitment to Alpha-1 Community

    PR NEWSWIRE

    FDA, EMA accept Pfizer`s hemophilia B gene therapy

    ENDPTS

    CSL doses first patient with haemophilia B gene therapy Hemgenix

    PHARMACEUTICAL TECHNOLOGY

    CSL`s Hemgenix (Etranacogene Dezaparvovec) Receives Approval in Europe

    EMA

    CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX

    PR NEWSWIRE

    CSL Behring Receives FDA Approval for Hizentra®

    PR NEWSWIRE

    New CEO Paul McKenzie plots CSL`s course for growth

    FIERCE PHARMA

    CSL Behring GmbH`s Hemgenix (etranacogene dezaparvovec) Receives Approval in Europe

    EMA

    CSL`s Hemgenix (etranacogene dezaparvovec) Approved In Europe

    EMA

    Orsini Specialty Pharmacy Selected by CSL Behring as a Limited Distribution

    PR NEWSWIRE

    CSL`s hemophilia B gene therapy works well through 24 months

    FIERCEPHARMA

    American Lung Association taps CSL Seqirus for flu vax campaign

    FIERCEPHARMA

    Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix

    FORBES

    Australia`s CSL prices hemophilia gene therapy at $3.5 million

    REUTERS

    BrightInsight Inks Enterprise Agreement with CSL Behring

    GLOBENEWSWIRE

    Can gene therapies for haemophilia defend their high price tags?

    PHARMACEUTICAL-TECHNOLOGY

    ICER Publishes Evidence Report on Gene Therapies for Hemophilia A and B

    ICER

    ICER says it`s fair for BioMarin &CSL toprice incoming hemophilia gene therapies

    ENDPTS

    CSL Receives Manufacturing & MKT Authorization in Japan for “Berinert S.C. Inj

    MARKETSCREENER

    CSL Behring teams with famous photographer to focus on hemophilia for campaign

    ENDPTS

    CSL-UniQure Hemophilia B Gene Therapy Scores Priority Review

    BIOSPACE

    Publication of definitive end result for Vifor Pharma tender offer

    BUSINESSWIRE

    CSL and Grifols sue US border patrol for blocking Mexican plasma donations

    ENDPTS

    Result for Vifor Pharma tender offer: CSL Behring declares offer successful

    BUSINESSWIRE

    Publication of provisional interim result for Vifor Pharma tender offer

    BUSINESSWIRE

    Pivotal HOPE-B Study Shows Therapeutic Effect of EtranaDez Gene Therapy

    PRNEWSWIRE

    CSL publishes Offer Prospectus on public tender offer for all shares of Vifor

    BUSINESSWIRE

    EMA Grants Accelerated Assessment for CSL Behring`s Haemophilia B Gene Therapy

    PRNEWSWIRE

    CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec

    PRNEWSWIRE

    uniQure & CSL Behring Announce Primary Endpoint Achieved in HOPE-B

    GLOBENEWSWIRE

    UniQure, CSL Behring dash to the FDA with a potential blockbuster gene therapy

    ENDPTS

    US FDA approves CSL Behring’s new Berinert administration kit

    PHARMABIZ

    With CSL all-in on AZ`s shot, Novavax hunts for Aussie partner

    FIERCE PHARMA

    CSL closes deal for UniQure gene therapy in hopeful sign for M&A

    BIOPHARMADIVE

    CSL Behring Announces Closing of Global Commercialization and License Agreement

    PRNEWSWIRE

    Research institute taps into RWE to assess angioedema therapies

    OUTSURCING-PHARMA

    Plasma therapy backed by CSL, Takeda fails phase 3 COVID-19 test

    FIERCE BIOTECH

    UniQure/CSL hem B gene therapy curbs bleeding in phase 3

    FIERCE BIOTECH

    CSL Behring and uniQure’s hemophilia B gene therapy hit its primary endpoint

    FIERCEBIOTECH

    Pharvaris lands another $80M as it looks to tackle Takeda and CSL

    ENDPTS

    Urban League, CSL Behring Partner to Address Community Needs Public Health

    PRNEWSWIRE

    Australian COVID-19 vaccine candidate produces antibody response in early tests

    REUTERS

    CSL Behring To Present New Real-World Data on Outcomes Acute Coronary Syndrome

    PRNEWSWIRE

    CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I

    PRNEWSWIRE

    Orphan Drug Granted for CSL Behring`s Investigational Plasma-Derived Hemopexin

    PRNEWSWIRE

    Australia signs deal with AstraZeneca for possible COVID-19 vaccine

    REUTERS

    CSL Behring evaluates monoclonal Ab for respiratory distress

    BIOSPECTRUMASIA

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.